Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex.
The pathology of acute disseminated encephalomyelitis produced experimentally in the rhesus monkey and its resemblance to human demyelinating disease.
The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system.
Viral triggers of multiple sclerosis.
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study.
Mycophenolate mofetil therapy in the management of inflammatory bowel disease - A retrospective case series and review.
Seeing illness in art and medicine: a patient and printmaker collaboration.
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
Positive results from Phase 3 CONFIRM clinical trial show efficacy and safety of oral BG-12 in multiple sclerosis
A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity.
[Recommendations for a brief international cognitive assessment for multiple sclerosis].
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study.
Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.
TECFIDERA® (dimethyl fumarate) approved in the European Union as a first-line oral treatment for multiple sclerosis
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.
The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells.
Recruiting women smokers: the engineering of consent.
Scientists probe strategies to repair neuron damage in multiple sclerosis.
SMC Says Yes to Aubagio® (teriflunomide), a New Once Daily First-line Oral Treatment Available for People with an Active Relapsing Remitting Form of MS
Gender as risk factor for autoimmune diseases.
BIIB033 single ascending dose study in healthy volunteer subjects
Improving the translational hit of experimental treatments in multiple sclerosis.
Use of fumaric acid esters in psoriasis.
Temporal trends in the incidence of multiple sclerosis: a systematic review.

Pages